Publicaciones

Ahmad O, Ahmad KE, Dear KB, Harvey I, Hughes A, Lueck CJ.
Atrial Fibrillation and Anticoagulation in a Stroke Unit Population.
Intern Med J. 2009 Sep 1. [Epub ahead of print]

Blackmer AB, Oertel MD, Valgus JM.
Fondaparinux and the Management of Heparin-Induced Thrombocytopenia: The Journey Continues.
Ann Pharmacother. 2009 Sep 8. [Epub ahead of print]

Bonaca MP, Morrow DA.
SCH 530348: a novel oral thrombin receptor antagonist.
Future Cardiol. 2009;5(5):435-42

Bover R, Pérez-Gómez F, Maluenda MP, Asenjo S, Pérez-Saldaña R, Igea A, Suárez M, Coleto D, Fernández C.
Long-Term Follow-Up of Atrial Fibrillation Patients in the NASPEAF Study. Prospective Evaluation of Different Antiplatelet Treatments.
Rev Esp Cardiol 2009;62(9):992-1000

Camm AJ.
The RE-LY study: Randomized Evaluation of Long-term anticoagulant therapY: dabigatran vs. warfarin.
Eur Heart J. 2009 Sep 21. [Epub ahead of print]

Connolly SJ, Crijns HJ, Torp-Pedersen C, van Eickels M, Gaudin C, Page RL, Hohnloser SH; for the ATHENA Investigators.
Analysis of Stroke in ATHENA: A Placebo-Controlled, Double-Blind, Parallel-Arm Trial to Assess the Efficacy of Dronedarone 400 mg BID for the Prevention of Cardiovascular Hospitalization or Death From Any Cause in Patients With Atrial Fibrillation/Atrial Flutter.
Circulation. 2009 Sep 14. [Epub ahead of print]

Connolly SJ, Ezekowitz MD., Yusuf S, Eikelboom J, Oldgren J, Parekh A, Pogue J, Reilly PA, Themeles E, Varrone J, Wang S, Alings M, Xavier D, Zhu J, Diaz R, Lewis BS, Darius H, Diener HC, Joyner CD, Wallentin L, the RE-LY Steering Committee and Investigators
Dabigatran versus Warfarin in Patients with Atrial Fibrillation.
N Engl J Med 2009;361(12):1139-51

De Assis MC, Rabelo ER, Avila CW, Polanczyk CA, Rohde LE.
Improved oral anticoagulation after a dietary vitamin k-guided strategy: a randomized controlled trial.
Circulation. 2009;120(12):1115-22, 3 p following 1122. Epub 2009 Sep 8

Dentali F, Ageno W, Witt D, Malato A, Clark N, Garcia D, McCool K, Siragusa S, Dyke S, Crowther M; for the WARPED consortium.
Natural history of mesenteric venous thrombosis in patients treated with vitamin K antagonists. A multi-centre, retrospective cohort study.
Thromb Haemost. 2009;102(3):501-504

Ellis DJ, Usman MH, Milner PG, Canafax DM, Ezekowitz MD.
The first evaluation of a novel vitamin K antagonist, tecarfarin (ATI-5923), in patients with atrial fibrillation.
Circulation. 2009;120(12):1029-35, 2 p following 1035. Epub 2009 Sep 8

Esmon CT.
Basic mechanisms and pathogenesis of venous thrombosis
Blood Rev 2009 Sep;23(5):225-9.

Fernlöf G, Sjöström BM, Lindell KM, Wall UE.
Management of major bleedings during anticoagulant treatment with the oral direct thrombin inhibitor ximelagatran or warfarin.
Blood Coagul Fibrinolysis. 2009 Sep 7. [Epub ahead of print]

Freedman JE, Gersh BJ.
New therapies for stroke prevention in atrial fibrillation: the long road to enhanced efficacy.
Circulation. 2009;120(12):1024-6.

Galanaud JP, Sevestre-Pietri MA, Bosson JL, Laroche JP, Righini M, Brisot D, Boge G, van Kien AK, Gattolliat O, Bettarel-Binon C, Gris JC, Genty C, Quere I; The OPTIMEV-SFMV Investigators.
Comparative study on risk factors and early outcome of symptomatic distal versus proximal deep vein thrombosis: Results from the OPTIMEV study.
Thromb Haemost. 2009;102(3):493-500

Gómez-Outes A, Suárez-Gea ML, Blázquez-Pérez A, Pozo-Hernández C, Vargas-Castrillón E.
Will oral rivaroxaban improve clinically relevant outcomes and thromboprophylaxis management in the orthopedic patient?
J Thromb Haemost 2009 Sep 18. [Epub ahead of print]

Hart RG, Halperin JL.
Do current guidelines result in overuse of warfarin anticoagulation in patients with atrial fibrillation?
Ann Intern Med 2009;151(5):355-6

Kahn SR.
How I manage the post thrombotic syndrome
Blood 2009 Sep 9. [Epub ahead of print]

Kakkar AK.
Prevention of Venous Thromboembolism in the Cancer Surgical Patient
J Clin Oncol. 2009 Sep 8. [Epub ahead of print]

Lee AY.
Anticoagulation in the Treatment of Established Venous Thromboembolism in Patients With Cancer.
J Clin Oncol. 2009 Sep 8. [Epub ahead of print]

Lepic K, Crowther MA
A logical approach to surgical thromboprophylaxis
Curr Opin Hematol 2009 Sep;16(5):397-401.

Meltzer ME, Doggen CJ, de Groot PG, Rosendaal FR, Lisman T.
The impact of the fibrinolytic system on the risk of venous and arterial thrombosis.
Semin Thromb Hemost. 2009 Jul;35(5):468-77. Epub 2009 Sep 8

No authors listed
Self-monitoring for patients on warfarin?
Drug Ther Bull. 2009;47(9):98-101

Piazza G, Fanikos J, Zayaruzny M, Goldhaber SZ.
Venous thromboembolic events in hospitalised medical patients.
Thromb Haemost. 2009;102(3):505-10

Singer DE, Chang Y, Fang MC, Borowsky LH, Pomernacki NK, Udaltsova N, Go AS.
The net clinical benefit of warfarin anticoagulation in atrial fibrillation.
The net clinical benefit of warfarin anticoagulation in atrial fibrillation. 2009;151(5):297-305

Spectre G, Varon D
New antiplatelet agents
Curr Opin Hematol 2009 Sep;16(5):365-70.

Streiff MB
Diagnosis and Initial Treatment of Venous Thromboembolism in Patients With Cancer.
J Clin Oncol. 2009 Sep 8. [Epub ahead of print]

Subramaniam V, Davis RC, Shantsila E, Lip GY.
Antithrombotic therapy for heart failure in sinus rhythm
Fundam Clin Pharmacol. 2009 Sep 4. [Epub ahead of print]

Zinn A, Feit F.
Optimizing antithrombotic strategies in patients with concomitant indications for warfarin undergoing coronary artery stenting.
Am J Cardiol. 2009 Sep 7;104(5 Suppl):49C-54C

Agnelli G, Gussoni G, Bianchini C, Verso M, Mandalà M, Cavanna L, Barni S, Labianca R, Buzzi F, Scambia G, Passalacqua R, Ricci S, Gasparini G, Lorusso V, Bonizzoni E, Tonato M; on behalf of the PROTECHT Investigators.
Nadroparin for the prevention of thromboembolic events in ambulatory patients with metastatic or locally advanced solid cancer receiving chemotherapy: a randomised, placebo-controlled, double-blind study.
Lancet Oncol. 2009 Aug 31. [Epub ahead of print]

Chan KE, Lazarus JM, Thadhani R, Hakim RM.
Warfarin Use Associates with Increased Risk for Stroke in Hemodialysis Patients with Atrial Fibrillation.
J Am Soc Nephrol 2009 Aug 27. [Epub ahead of print]

Chandrasekaran S, Ariaretnam SK, Tsung J, Dickison D.
Early mobilization after total knee replacement reduces the incidence of deep venous thrombosis
ANZ J Surg 2009;79(7-8):526-9.

Crandall MA, Horne BD, Day JD, Anderson JL, Muhlestein JB, Crandall BG, Weiss JP, Osborne JS, Lappé DL, Bunch TJ.
Atrial fibrillation significantly increases total mortality and stroke risk beyond that conveyed by the CHADS2 risk factors
Pacing Clin Electrophysiol 2009 Aug;32(8):981-6.

Crowther MA, Warkentin TE.
Managing bleeding in anticoagulated patients with a focus on novel therapeutic agents
J Thromb Haemost 2009;7 Suppl 1:107-10.

De Caterina R
The current role of anticoagulants in cardiovascular medicine
J Cardiovasc Med (Hagerstown) 2009 Aug;10(8):595-604

Dobesh PP.
Economic burden of venous thromboembolism in hospitalized patients
Pharmacotherapy 2009;29(8):943-53

Fitzmaurice D.
Atrial fibrillation and coagulation: Who and when?
Blood Rev. 2009 Aug 24. [Epub ahead of print]

Francis CW.
Prevention of Venous Thromboembolism in Hospitalized Patients With Cancer.
J Clin Oncol. 2009 Aug 24. [Epub ahead of print]

Gage BF.
Can we rely on RE-LY?
N Engl J Med. 2009;361(12):1200-2. Epub 2009 Aug 30

Karami-Djurabi R, Klok FA, Kooiman J, Velthuis SI, Nijkeuter M, Huisman MV.
D-dimer Testing in Patients with Suspected Pulmonary Embolism and Impaired Renal Function
Am J Med 2009 Aug 19. [Epub ahead of print]

Kearon C.
Balancing risks and benefits of extended anticoagulant therapy for idiopathic venous thrombosis.
J Thromb Haemost2009;7 Suppl 1:296-300.

Kessler CM.
The link between cancer and venous thromboembolism: a review
Am J Clin Oncol 2009;32(4 Suppl):S3-7.

Kössler J, Steigerwald U, Walter U.
Anticoagulants of primary haemostasis.
Hamostaseologie 2009;29(3):274-278

Lassen MR, Raskob GE, Gallus A, Pineo G, Chen D, Portman RJ
Apixaban or enoxaparin for thromboprophylaxis after knee replacement.
N Engl J Med 2009;361:594-604.

Macfarlane AJ, Prasad GA, Chan VW, Brull R.
Does regional anaesthesia improve outcome after total hip arthroplasty? A systematic review.
Br J Anaesth 2009;103(3):335-45.

Neviaser AS, Chang C, Lyman S, Gonzales Della Valle A, Haas SB.
High Incidence of Complications From Enoxaparin Treatment After Arthroplasty
Clin Orthop Relat Res 2009 Aug 11. [Epub ahead of print]

Ordovás Baines JP.
Dabigatran and rivaroxaban, new oral anticoagulants for the treatment of venous thromboembolism.
Farm Hosp. 2009;33(3):123-4

Palareti G, Cosmi B.
Bleeding with anticoagulation therapy - Who is at risk, and how best to identify such patients.
Thromb Haemost 2009;102(2):268-78.

Quist-Paulsen P, Næss IA, Cannegieter SC, Romundstad PR, Christiansen SC, Rosendaal FR, Hammerstrøm J.
Arterial cardiovascular risk factors and venous thrombosis: results from a population based prospective study (the HUNT 2)
Haematologica. 2009 Aug 27. [Epub ahead of print]

Sanoski CA.
Clinical, Economic, and Quality of Life Impact of Atrial Fibrillation
J Manag Care Pharm 2009;15(6 Supp B):1-9.

Schulman S, Reilly PA.
Dabigatran Etexilate: Future Directions in Anticoagulant Treatment.
Clin Appl Thromb Hemost 2009 Aug 13. [Epub ahead of print]

Schulman S.
Rivaroxaban in Orthopedic Surgery: A Change of Paradigm?
Clin Appl Thromb Hemost 2009 Aug 10. [Epub ahead of print]

Scott SA, Jaremko M, Lubitz SA, Kornreich R, Halperin JL, Desnick RJ.
CYP2C9*8 is prevalent among African-Americans: implications for pharmacogenetic dosing.
Pharmacogenomics 2009;10(8):1243-55.

Stangier J, Clemens A.
Pharmacology, Pharmacokinetics, and Pharmacodynamics of Dabigatran Etexilate, an Oral Direct Thrombin Inhibitor
Clin Appl Thromb Hemost 2009 Aug 19. [Epub ahead of print]

Steffel J, Lüscher TF
Novel anticoagulants in clinical development: focus on factor Xa and direct thrombin inhibitors
J Cardiovasc Med (Hagerstown) 2009 Aug;10(8):616-23.

TRA*CER Executive and Steering Committees.
The Thrombin Receptor Antagonist for Clinical Event Reduction in Acute Coronary Syndrome (TRA*CER) trial: study design and rationale.
Am Heart J 2009;158(3):327-334.e4.

Verdú A, Maestre A, López P, Gil V, Martín-Hidalgo A, Castaño JA.
Clinical pathways as a healthcare tool: design, implementation and assessment of a clinical pathway for lower-extremity deep venous thrombosis
Qual Saf Health Care 2009;18(4):314-20.

Camporese G, Bernardi E
Low-molecular-weight heparin for thromboprophylaxis
Curr Opin Pulm Med 2009 Jul 9

Crandall MA, Bradley DJ, Packer DL, Asirvatham SJ
Contemporary management of atrial fibrillation: update on anticoagulation and invasive management strategies
Mayo Clin Proc 2009 Jul;84(7):643-62

Johanson NA, Lachiewicz PF, Lieberman JR, Lotke PA, Parvizi J, Pellegrini V, Stringer TA, Tornetta P 3rd, Haralson RH 3rd, Watters WC 3rd
American academy of orthopaedic surgeons clinical practice guideline on. Prevention of symptomatic pulmonary embolism in patients undergoing total hip or knee arthroplasty
J Bone Joint Surg Am 2009 Jul;91(7):1756-7

Prandoni P, Pesavento R, Sørensen HT, Gennaro N, Dalla Valle F, Minotto I, Perina F, Pengo V, Pagnan A.
Prevalence of heart diseases in patients with pulmonary embolism with and without peripheral venous thrombosis: findings from a cross-sectional survey.
Eur J Intern Med 2009;20(5):470-3. Epub 2009 Jul 4

Scarvelis D, Anderson J, Davis L, Forgie M, Lee J, Petersson L, Ramsay T, Wells PS.
Hospital mortality due to pulmonary embolism and an evaluation of the usefulness of preventative interventions
Thromb Res 2009 Jul 30. [Epub ahead of print]

Schulman S, Melinyshyn A, Ennis D, Rudd-Scott L.
Single-dose adjustment versus no adjustment of warfarin in stably anticoagulated patients with an occasional international normalized ratio (INR) out of range
Thromb Res 2009 Jul 28 [Epub ahead of print]

Spencer FA, Emery C, Joffe SW, Pacifico L, Lessard D, Reed G, Gore JM, Goldberg RJ
Incidence rates, clinical profile, and outcomes of patients with venous thromboembolism. The Worcester VTE study
J Thromb Thrombolysis 2009 Jul 24. [Epub ahead of print]

Turpie AG
Direct Factor Xa and direct thrombin inhibitors: A clinical trial update
Curr Opin Drug Discov Devel 2009 Jul;12(4):497-508

Ageno W.
Rivaroxaban for the prevention of venous thromboembolism following major orthopedic surgery: the RECORD trials.
Expert Rev Cardiovasc Ther 2009;7:569-76

Amin A, Spyropoulos AC, Dobesh P, Shorr A, Hussein M, Mozaffari E, Benner JS
Are hospitals delivering appropriate VTE prevention? The venous thromboembolism study to assess the rate of thromboprophylaxis (VTE start)
Thromb Thrombolysis2009 Jun 23. [Epub ahead of print]

Borris LC
Rivaroxaban and dabigatran etexilate: two new oral anticoagulants for extended postoperative prevention of venous thromboembolism after elective total hip arthroplasty
Arch Orthop Trauma Surg 2009 Jun 30. [Epub ahead of print]

Bump GM, Dandu M, Kaufman SR, Shojania KG, Flanders SA
How complete is the evidence for thromboembolism prophylaxis in general medicine patients? A meta-analysis of randomized controlled trials
J Hosp Med 2009;4(5):289-97

Debourdeau P, Kassab Chahmi D, Le Gal G, Kriegel I, Desruennes E, Douard MC, Elalamy I, Meyer G, Mismetti P, Pavic M, Scrobohaci ML, Lévesque H, Renaudin JM, Farge D; on behalf of the working group of the SOR
2008 SOR guidelines for the prevention and treatment of thrombosis associated with central venous catheters in patients with cancer: report from the working group
Ann Oncol 2009 Jun 12 [Epub ahead of print]

Deinum J, Mattsson C, Inghardt T, Elg M
Biochemical and pharmacological effects of the direct thrombin inhibitor AR-H067637
Thromb Haemost 2009;101:1051-9

Garcia D
Novel anticoagulants and the future of anticoagulation.
Thromb Res 2009;123 Suppl 4:S50-5

Halbfass P, Janko S, Dorwarth U, Riess G, Antoni D, Hoffmann E
Dilemma of antithrombotic therapy in anticoagulated atrial fibrillation patients squeezed between thrombosis and bleeding events: a single-centre experience.
Europace 2009 Jun 3 [Epub ahead of print]

Klok FA, Mos IC, Broek L, Tamsma JT, Rosendaal FR, de Roos A, Huisman MV
Risk of arterial cardiovascular events in patients after pulmonary embolism.
Blood 2009 Aug 20;114(8):1484-8. Epub 2009 Jun 23.

Kucher N, Puck M, Blaser J, Bucklar G, Eschmann E, Lüscher TF.
Physician compliance with advanced electronic alerts for preventing venous thromboembolism among hospitalized medical patients.
J Thromb Haemost 2009 Jun 9 [Epub ahead of print]

Masaki N, Suzuki M, Iwatsuka R, Mizukami A, Kumasaka L, Nagahori W, Ohno M, Matsumura A, Maruyama Y, Hashimoto Y
Effectiveness of Risk Stratification According to CHADS2 Score in Japanese Patients With Nonvalvular Atrial Fibrillation.
Int Heart J 2009;50(3):323-9

McAndrew CM, Fitzgerald SJ, Kraay MJ, Goldberg VM
Incidence of Postthrombotic Syndrome in Patients Undergoing Primary Total Knee Arthroplasty for Osteoarthritis.
Clin Orthop Relat Res 2009 Jun 19. [Epub ahead of print]

Mega J, Braunwald E, Mohanavelu S, Burton P, Poulter R, Misselwitz F, Hricak V, Barnathan E, Bordes P, Witkowski A, Markov V, Oppenheimer L, Gibson C; on behalf of the ATLAS ACS-TIMI 46 study group.
Rivaroxaban versus placebo in patients with acute coronary syndromes (ATLAS ACS-TIMI 46): a randomised, double-blind, phase II trial.
Lancet 2009 Jun 16. [Epub ahead of print]

Nadar SK, Goyal D, Shantsila E, Banerjee P, Lip GY
Fondaparinux: an overview.
Expert Rev Cardiovasc Ther 2009 Jun;7(6):577-85

Ng HJ, Lee LH
Trends in prevalence of deep venous thrombosis among hospitalised patients in an Asian institution.
Thromb Haemost 2009;10:1095-9

Nokes TJ, Keenan J.
Thromboprophylaxis in patients with lower limb immobilisation - review of current status.
Br J Haematol 2009 Jun 10 [Epub ahead of print]

Nutescu EA, Spinler SA, Wittkowsky A, Dager WE
Low-molecular-weight heparins in renal impairment and obesity: available evidence and clinical practice recommendations across medical and surgical settings.
Ann Pharmacother 2009 Jun;43(6):1064-83

Park B, Messina L, Dargon P, Huang W, Ciocca R, Anderson FA
Recent Trends in Clinical Outcomes and Resource Utilization for Pulmonary Embolism in the United States: Findings From the Nationwide Inpatient Sample.
Chest 2009 Jun 12 [Epub ahead of print]

Pengo V, Cucchini U, Denas G, Erba N, Guazzaloca G, La Rosa L, De Micheli V, Testa S, Frontoni R, Prisco D, Nante G, Iliceto S; Italian Federation of Centers for the Diagnosis of Thrombosis and Management of Antithrombotic Therapies (FCSA)
Standardized low-molecular-weight heparin bridging regimen in outpatients on oral anticoagulants undergoing invasive procedure or surgery: an inception cohort management study.
Circulation 2009 Jun 9;119(22):2920-7

Pineo GF, Hull RD
Economic and Practical Aspects of Thromboprophylaxis With Unfractionated and Low-Molecular-Weight Heparins in Hospitalized Medical Patients.
Clin Appl Thromb Hemost 2009 Jun 10. [Epub ahead of print]

Prineas RJ, Soliman EZ, Howard G, Howard VJ, Cushman M, Zhang ZM, Moy CS
The sensitivity of the method used to detect atrial fibrillation in population studies affects group-specific prevalence estimates: ethnic and regional distribution of atrial fibrillation in the REGARDS study
J Epidemiol 2009;19(4):177-81. Epub 2009 Jun 27

Shantsila E, Lip GY, Chong BH
Heparin-induced thrombocytopenia. A contemporary clinical approach to diagnosis and management.
Chest 2009 Jun; 135(6):1651-64

Sorensen SV, Dewilde S, Singer DE, Goldhaber SZ, Monz BU, Plumb JM
Cost-effectiveness of warfarin: trial versus "real-world" stroke prevention in atrial fibrillation.
Am Heart J 2009;157:1064-73

Volkmann H, Walter M, Bergmann C, Rose E, Krpciar V, Vetter S
Antithrombotic therapy in atrial fibrillation : When vitamin K antagonists? When aspirin? When heparine? When combinations of anticoagulant and antiplatelet drugs?
Herzschrittmacherther Elektrophysiol 2009 Jun 20 [Epub ahead of print] German

Wakefield TW, McLafferty RB, Lohr JM, Caprini JA, Gillespie DL, Passman MA; Executive Committee of the American Venous Forum
Call to action to prevent venous thromboembolism.
J Vasc Surg 2009 Jun;49(6):1620-3

Wells PS, Le Gal G, Tierney S, Carrier M
Practical application of the 10-mg warfarin initiation nomogram.
Blood Coagul Fibrinolysis 2009 Jun 10. [Epub ahead of print]

APPRAISE Steering Committee and Investigators, Alexander JH, Becker RC, Bhatt DL, Cools F, Crea F, Dellborg M, Fox KA, Goodman SG, Harrington RA, Huber K, Husted S, Lewis BS, Lopez-Sendon J, Mohan P, Montalescot G, Ruda M, Ruzyllo W, Verheugt F, Wallentin L
Apixaban, an oral, direct, selective factor Xa inhibitor, in combination with antiplatelet therapy after acute coronary syndrome: results of the Apixaban for Prevention of Acute Ischemic and Safety Events (APPRAISE) trial.
Circulation 2009;119:2877-85.

Cook D, Tkaczyk A, Lutz K, McMullin J, Haynes RB, Douketis J
Thromboprophylaxis for hospitalized medical patients: a multicenter qualitative study.
J Hosp Med 2009 May;4(5):269-75.

Cusick LA, Beverland DE
The incidence of fatal pulmonary embolism after primary hip and knee replacement in a consecutive series of 4253 patients
J Bone Joint Surg Br 2009 May;91(5):645-8

Eriksson BI, Kakkar AK, Turpie AG, Gent M, Bandel TJ, Homering M, Misselwitz F, Lassen MR
Oral rivaroxaban for the prevention of symptomatic venous thromboembolism after elective hip and knee replacement
J Bone Joint Surg Br 2009 May;91(5):636-44

Ezekowitz MD, Connolly S, Parekh A, Reilly PA, Varrone J, Wang S, Oldgren J, Themeles E, Wallentin L, Yusuf S
Rationale and design of RE-LY: randomized evaluation of long-term anticoagulant therapy, warfarin, compared with dabigatran
Am Heart J 2009 May;157(5):805-10, 810.e1-2

Persson LM, Lapidus LJ, Lärfars G, Rosfors S
Asymptomatic Deep Venous Thrombosis is Associated with a Low Risk of Post-thrombotic Syndrome.
Eur J Vasc Endovasc Surg 2009 May 29 [Epub ahead of print]

Poli D, Antonucci E, Grifoni E, Abbate R, Gensini GF, Prisco D
Gender differences in stroke risk of atrial fibrillation patients on oral anticoagulant treatment.
Thromb Haemost. 2009 May;101(5):938-42

Poli D, Antonucci E, Grifoni E, Abbate R, Gensini GF, Prisco D.
Bleeding risk during oral anticoagulation in atrial fibrillation patients older than 80 years.
J Am Coll Cardiol. 2009;54(11):999-1002

Prandoni P, Prins MH, Lensing AW, Ghirarduzzi A, Ageno W, Imberti D, Scannapieco G, Ambrosio GB, Pesavento R, Cuppini S, Quintavalla R, Agnelli G; AESOPUS Investigators
Residual thrombosis on ultrasonography to guide the duration of anticoagulation in patients with deep venous thrombosis: a randomized trial.
Ann Intern Med 2009 May 5;150(9):577-85

Squizzato A, Micieli E, Galli M, Gibson N, Gerdes VE, Dentali F, Buller H, Ageno W, Venco A
Diagnosis and management of venous thromboembolism: Results of a survey on current clinical practice.
Thromb Res 2009 May 19 [Epub ahead of print]

Turpie AG, Lassen MR, Davidson BL, Bauer KA, Gent M, Kwong LM, Cushner FD, Lotke PA, Berkowitz SD, Bandel TJ, Benson A, Misselwitz F, Fisher WD; for the RECORD4 Investigators.
Rivaroxaban versus enoxaparin for thromboprophylaxis after total knee arthroplasty (RECORD4): a randomised trial
Lancet 2009 May 1 [Epub ahead of print]

Baker WL, Cios DA, Sander SD, Coleman CI
Meta-analysis to assess the quality of warfarin control in atrial fibrillation patients in the United States.
J Manag Care Pharm 2009 Apr;15(3):244-52

Borris LC
Rivaroxaban, a new, oral, direct factor Xa inhibitor for thromboprophylaxis after major joint arthroplasty
Expert Opin Pharmacother2009 Apr;10(6):1083-8

Chin PL, Amin MS, Yang KY, Yeo SJ, Lo NN
Thromboembolic prophylaxis for total knee arthroplasty in Asian patients: a randomised controlled trial
J Orthop Surg (Hong Kong) 2009 Apr;17(1):1-5

De Caterina R, Kristensen SD, Renda G
New anticoagulants for atrial fibrillation
J Cardiovasc Med (Hagerstown)2009 Apr 10

Enden T, Kløw NE, Sandvik L, Slagsvold CE, Ghanima W, Hafsahl G, Holme PA, Holmen LO, Njaastad AM, Sandbæk G, Sandset PM; For the Cavent Study Group
Catheter-directed thrombolysis versus anticoagulant therapy alone in deep vein thrombosis: results of an open randomized, controlled trial reporting on short term patency
J Thromb Haemost 2009 Apr 30. [Epub ahead of print]

Jiang X, Crain EJ, Luettgen JM, Schumacher WA, Wong PC
Apixaban, an oral direct factor Xa inhibitor, inhibits human clot-bound factor Xa activity in vitro
Thromb Haemost 2009 Apr;101(4):780-2

Lassen MR, Dahl OE, Mismetti P, Destrée D, Turpie AG
AVE5026, a new hemisynthetic ultra-low-molecular-weight heparin for the prevention of venous thromboembolism in patients after total knee replacement surgery--TREK: a dose-ranging study.
J Thromb Haemost 2009 Apr;7(4):566-72. Epub 2009 Jan 24

Merli GJ
Deep-vein thrombosis in malignancy: How long should patients be treated, and with what?
Catheter Cardiovasc Interv 2009 Apr 13;74(S1):S27-S34. [Epub ahead of print]

Nabauer M, Gerth A, Limbourg T, Schneider S, Oeff M, Kirchhof P, Goette A, Lewalter T, Ravens U, Meinertz T, Breithardt G, Steinbeck G.
The Registry of the German Competence NETwork on Atrial Fibrillation: patient characteristics and initial management.
Europace. 2009 Apr; 11(4):423-34 [Epub 2009 Jan 18]

Nicolau JC, Cohen M, Montalescot G
Differences Among Low-Molecular Weight Heparins: Evidence in Patients With Acute Coronary Syndromes.
J Cardiovasc Pharmacol 2009 Apr 10. [Epub ahead of print]

van Walraven C, Hart RG, Connolly S, Austin PC, Mant J, Hobbs FD, Koudstaal PJ, Petersen P, Perez-Gomez F, Knottnerus JA, Boode B, Ezekowitz MD, Singer DE.
Effect of age on stroke prevention therapy in patients with atrial fibrillation: the atrial fibrillation investigators.
Stroke 2009 Apr;40(4):1410-6. Epub 2009 Jan 29

Becker RC, Moliterno DJ, Jennings LK, Pieper KS, Pei J, Niederman A, Ziada KM, Berman G, Strony J, Joseph D, Mahaffey KW, Van de Werf F, Veltri E, Harrington RA; TRA-PCI Investigators
Safety and tolerability of SCH 530348 in patients undergoing non-urgent percutaneous coronary intervention: a randomised, double-blind, placebo-controlled phase II study
Lancet 2009 Mar 14;373(9667):919-28

Cohen AT, Maillardet L, Yavin Y
Will a once-weekly anticoagulant for the treatment and secondary prevention of thromboembolism improve adherence?
Thromb Haemost 2009 Mar;101(3):422-7

Go AS, Fang MC, Udaltsova N, Chang Y, Pomernacki NK, Borowsky L, Singer DE; ATRIA Study Investigators
Impact of proteinuria and glomerular filtration rate on risk of thromboembolism in atrial fibrillation: the anticoagulation and risk factors in atrial fibrillation (ATRIA) study.
Circulation 2009 Mar 17;119(10):1363-9. Epub 2009 Mar 2

Johanson NA, Lachiewicz PF, Lieberman JR, Lotke PA, Parvizi J, Pellegrini V, Stringer TA, Tornetta P 3rd, Haralson RH 3rd, Watters WC 3rd
Prevention of symptomatic pulmonary embolism in patients undergoing total hip or knee arthroplasty.
J Am Acad Orthop Surg 2009 Mar;17(3):183-96

Poller L, Keown M, Ibrahim S, Lowe G, Moia M, Turpie AG, Roberts C, van den Besselaar AM, van der Meer FJ, Tripodi A, Palareti G, Shiach C, Bryan S, Samama M, Burgess-Wilson M, Heagerty A, Maccallum P, Wright D, Jespersen J; European Action on Anticoagulation (EAA)
A multicentre randomised assessment of the DAWN AC computer-assisted oral anticoagulant dosage program.
Thromb Haemost 2009 Mar;101(3):487-94

Rietbrock S, Plumb JM, Gallagher AM, van Staa TP
How effective are dose-adjusted warfarin and aspirin for the prevention of stroke in patients with chronic atrial fibrillation? An analysis of the UK General Practice Research Database.
Thromb Haemost 2009 Mar;101(3):527-34

Rochat MC, Waeber G, Wasserfallen JB, Nakov K, Aujesky D
Hospitalized women experiencing an episode of excessive oral anticoagulation had a higher bleeding risk than men.
J Womens Health (Larchmt) 2009 Mar; 18(3):321-6

Spence D
Mechanisms of thrombogenesis in atrial fibrillation.
Lancet. 2009 Mar 21; 373(9668):1006

Stashenko GJ, Hargett CW, Tapson VFm
Thrombolytic therapy for venous thromboembolism: Current clinical practice.
J Hosp Med. 2009 Mar 5. [Epub ahead of print]

White RH, Keenan CR
Effects of race and ethnicity on the incidence of venous thromboembolism.
Thromb Res. 2009;123 Suppl 4:S11-7

Bounameaux H
The novel anticoagulants: entering a new era
Swiss Med Wkly 2009 Feb 7;139(5-6):60-4

Chapman NH, Brighton T, Harris MF, Caplan GA, Braithwaite J, Chong BH
Venous thromboembolism - management in general practice
Aust Fam Physician 2009 Jan-Feb;38(1-2):36-40

Dranitsaris G, Stumpo C, Smith R, Bartle W
Extended dalteparin prophylaxis for venous thromboembolic events: cost-utility analysis in patients undergoing major orthopedic surgery
Am J Cardiovasc Drugs 2009;9(1):45-58. doi: 10.2165/00129784-200909010-00005

Eikelboom JW, Karthikeyan G, Fagel N, Hirsh J
American association of orthopedic surgeons and american college of chest physicians guidelines for venous thromboembolism prevention in hip and knee arthroplasty differ: what are the implications for clinicians and patients?
Chest. 2009 Feb;135(2):513-20

Haas S
New anticoagulants - towards the development of an "ideal" anticoagulant.
Vasa 2009 Feb;38(1):13-29

Harenberg J
Development of new anticoagulants: present and future.
Semin Thromb Hemost 2008 Nov;34(8):779-93. Epub 2009 Feb 12

Lang D, Weinz C, Schwarz T, Kubitza D, Mueck W
Metabolism and excretion of rivaroxaban - an oral, direct Factor Xa inhibitor - in rats, dogs and humans
Drug Metab Dispos 2009 Feb 5 [Epub ahead of print]

Prandoni P, Kahn SR
Post-thrombotic syndrome: prevalence, prognostication and need for progress.
Br J Haematol 2009 Feb 12. [Epub ahead of print]

Tripodi A, van den Besselaar A
Laboratory monitoring of anticoagulation: where do we stand?
Semin Thromb Hemost. 2009 Feb;35(1):34-41. Epub 2009 Mar 23.

Abrams PJ, Emerson CR.
Rivaroxaban: a novel, oral, direct factor xa inhibitor.
Pharmacotherapy. 2009;29:167-81

Beam DM, Courtney DM, Kabrhel C, Moore CL, Richman PB, Kline JA
Risk of Thromboembolism Varies, Depending on Category of Immobility in Outpatients
Ann Emerg Med. 2009 Jan 7. [Epub ahead of print]

Bryniarski L, Pelc-Nowicka A, Zabojszcz M, Mirek-Bryniarska E
Dual antiplatelet therapy and antithrombotic treatment: Recommendations and controversies
Cardiol J 2009;16(2):179-189

Eikelboom JE, Weitz JI
Dabigatran etexilate for prevention of venous thromboembolism
Thromb Haemost 2009 101:2-4

Eriksson BI, Quinlan DJ, Weitz JI
Comparative pharmacodynamics and pharmacokinetics of oral direct thrombin and factor xa inhibitors in development
Clin Pharmacokinet 2009;48(1):1-22. doi: 10.2165/0003088-200948010-00001

Farley TM, Lewis D, Macaulay TE
In the pipeline: new oral anticoagulants for the prevention of venous thromboembolism.
Orthopedics 2009 Jan;32(1) pii: orthosupersite.com/view.asp?rID=35867.

Haas S
Rivaroxaban - an oral, direct Factor Xa inhibitor: lessons from a broad clinical study programme.
Eur J Haematol 2009 Jan 29 [Epub ahead of print]

Karthikeyan G, Eikelboom JW, Hirsh J
New oral anticoagulants: not quite there yet.
Pol Arch Med Wewn 2009 Jan-Feb;119(1-2):53-8

Labarère J, Sevestre MA, Belmin J, Legagneux A, Barrellier MT, Thiel H, Roux PL, Pernod G, Bosson JL; for the Association pour la Promotion de l'Angiologie Hospitalière (APAH)
Low-Molecular-Weight Heparin Prophylaxis of Deep Vein Thrombosis for Older Patients with Restricted Mobility: Propensity Analyses of Data from Two Multicentre, Cross-Sectional Studies.
Drugs Aging 2009;26(3):263-271

Lassen MR, Dahl OE, Mismetti P, Destrée D, Turpie AG
AVE5026, a new hemisynthetic ultra-low-molecular-weight heparin for the prevention of venous thromboembolism in patients after total knee replacement surgery - TREK: a dose-ranging study.
J Thromb Haemost 2009 Jan 24 [Epub ahead of print]

Monkman K, Lazo-Langner A, Kovacs MJ
A 10 mg warfarin initiation nomogram is safe and effective in outpatients starting oral anticoagulant therapy for venous thromboembolism.
Thromb Res. 2009 Jan 18. [Epub ahead of print]

Mosca L, Grady D, Barrett-Connor E, et al.
Effect of raloxifene on stroke and venous thromboembolism according to subgroups in postmenopausal women at increased risk of coronary heart disease.
Stroke 2009 Jan;40(1):147-55. Epub 2008 Oct 23.

Pomp ER, Doggen CJ, Vos HL, Reitsma PH, Rosendaal FR
Polymorphisms in the protein C gene as risk factor for venous thrombosis.
Thromb Haemost 2009;101:62-7.

Rasmussen MS, Jorgensen LN, Wille-Jorgensen P
Prolonged thromboprophylaxis with low molecular weight heparin for abdominal or pelvic surgery.
Cochrane Database Syst Rev 2009 Jan 21(1):CD004318.

Siragusa S, Caramazza D, Malato A
How should we determine length of anticoagulation after proximal deep vein thrombosis of the lower limbs?
Br J Haematol. 2009 Jan 16. [Epub ahead of print]

Spiess JL
Can I stop the warfarin? A review of the risks and benefits of discontinuing anticoagulation
J Palliat Med 2009 Jan; 12(1):83-7

Taliani MR, et al.
Duration of anticoagulant treatment and recurrence of venous thromboembolism in patients with and without thrombophilic abnormalities.
Thromb Haemost. 2009; 101(3):596-598

Wolowacz SE, Roskell NS, Maciver F, Beard SM, Robinson PA, Plumb JM, Dolan G, Brenkel IJ
Economic evaluation of dabigatran etexilate for the prevention of venous thromboembolism after total knee and hip replacement surgery.
Clin Ther. 2009 Jan; 31(1):194-212

Akl EA, Terrenato I, Barba M, Sperati F, Muti P, Schünemann HJ.
Extended perioperative thromboprophylaxis in patients with cancer. A systematic review.
Thromb Haemost. 2008;100:1

Arora RR, Rai F
Antiplatelet Intervention in Acute Coronary Syndrome.
Am J Ther. 2008 Dec 15. [Epub ahead of print]

Baroletti S, Piovella C, Fanikos J, Labreche M, Lin J, Goldhaber SZ
Heparin-induced thrombocytopenia (HIT): Clinical and economic outcomes
Thromb Haemost 2008;100:1130-5

Borris LC
New compounds in the management of venous thromboembolism after orthopedic surgery: focus on rivaroxaban
Vasc Health Risk Manag. 2008;4(4):855-62.

Bounameaux H, Perrier A
Duration of anticoagulation therapy for venous thromboembolism
Hematology Am Soc Hematol Educ Program 2008;2008:252-8

Chintala M, Shimizu K, Ogawa M, Yamaguchi H, Doi M, Jensen P
Basic and translational research on proteinase-activated receptors: antagonism of the proteinase-activated receptor 1 for thrombin, a novel approach to antiplatelet therapy for atherothrombotic disease
J Pharmacol Sci 2008;108(4):433-8

Francis CW
New issues in oral anticoagulants
Hematology Am Soc Hematol Educ Program 2008;2008:259-65

Hill CE, Duncan A
Overview of pharmacogenetics in anticoagulation therapy.
Clin Lab Med 2008 Dec;28(4):513-24

Morgan CL, McEwan P, Tukiendorf A, Robinson PA, Clemens A, Plumb JM
Warfarin treatment in patients with atrial fibrillation: Observing outcomes associated with varying levels of INR control.
Thromb Res. 2008 Dec 3. [Epub ahead of print]

Pesce V, Patella V, Scaraggi A, Petrera M, Sammarco G
Thrombocytopenia after total knee arthroplasty.
Orthopedics 2008 Dec;31(12). pii: orthosupersite.com/view.asp?rID=32934.

Righini M, Le Gal G, Aujesky D, Roy PM, Sanchez O, Verschuren F, Kossovsky M, Bressollette L, Meyer G, Perrier A, Bounameaux H
Complete venous ultrasound in outpatients with suspected pulmonary embolism.
J Thromb Haemost 2008 Dec 20 [Epub ahead of print]

Tay KH, Lane DA, Lip GY
Bleeding risks with combination of oral anticoagulation plus antiplatelet therapy: is clopidogrel any safer than aspirin when combined with warfarin?
Thromb Haemost 2008; 100:955-7

Conget F, Otero R, Jiménez D, Martí D, Escobar C, Rodríguez C, Uresandi F, Cabezudo MA, Nauffal D, Oribe M, Yusen R
Short-term clinical outcome after acute symptomatic pulmonary embolism
Thromb Haemost 2008 Nov;100(5):937-42

Deitelzweig SB, Becker R, Lin J, Benner J.
Comparison of the two-year outcomes and costs of prophylaxis in medical patients at risk of venous thromboembolism
Thromb Haemost 2008 Nov;100(5):810-20

Franchini M, Mannucci PM
Venous and arterial thrombosis: different sides of the same coin?
Eur J Intern Med 2008 Nov;19(7):476-81. Epub 2008 Mar 20

Glurich I, Burmester JK, Caldwell MD
Understanding the pharmacogenetic approach to warfarin dosing
Heart Fail Rev 2008 Nov 8. [Epub ahead of print]

Heck CA, Brown CR, Richardson WJ
Venous thromboembolism in spine surgery.
J Am Acad Orthop Surg 2008 Nov;16(11):656-64

Hunt BJ
The prevention of hospital-acquired venous thromboembolism in the United Kingdom
Br J Haematol 2008 Nov 29 [Epub ahead of print]

Janjua M, Badshah A, Matta F, Danescu LG, Yaekoub AY, Stein PD
Treatment of acute pulmonary embolism as outpatients or following early discharge. A systematic review.
Thromb Haemost 2008 Nov;100(5):756-61

Kahn SR, Shrier I, Julian JA, Ducruet T, Arsenault L, Miron MJ, Roussin A, Desmarais S, Joyal F, Kassis J, Solymoss S, Desjardins L, Lamping DL, Johri M, Ginsberg JS
Determinants and time course of the postthrombotic syndrome after acute deep venous thrombosis.
Ann Intern Med 2008 Nov 18;149(10):698-707

Levy JH, Tanaka KA, Dietrich W
Perioperative hemostatic management of patients treated with vitamin K antagonists
Anesthesiology 2008 Nov;109(5):918-26

Milbrink J, Bergqvist D
The incidence of symptomatic venous thromboembolic events in orthopaedic surgery when using routine thromboprophylaxis.
Vasa. 2008 Nov;37(4):353-7

Millar JA
Rational thromboprophylaxis in medical inpatients: not quite there yet.
Med J Aust 2008 Nov 3;189(9):504-6.

Nieto JA, Camara T, Gonzalez-Higueras E, Ruiz-Gimenez N, Guijarro R, Marchena PJ, Monreal M; for the RIETE Investigators.
Clinical outcome of patients with major bleeding after venous thromboembolism. Findings from the RIETE Registry.
Thromb Haemost 2008;100(5):789-796.

Roldán V, Marín F
Contra: 'Antithrombotic therapy with warfarin, aspirin and clopidogrel is the recommended regimen in anticoagulated patients who present with an acute coronary syndrome and/or undergo percutaneous coronary interventions'. Not for everybody.
Thromb Haemost. 2008 Nov;100(5):754-5.

Rubboli A, Halperin JL
Pro: 'Antithrombotic therapy with warfarin, aspirin and clopidogrel is the recommended regime in anticoagulated patients who present with an acute coronary syndrome and/or undergo percutaneous coronary interventions'.
Thromb Haemost. 2008 Nov; 100(5):752-3

Selby R, Geerts W, Ofosu FA, Craven S, Dewar L, Phillips A, Szalai JP
Hypercoagulability after trauma: Hemostatic changes and relationship to venous thromboembolism.
Thromb Res 2008 Nov 26 [Epub ahead of print]

Thachil J, Gatt A, Martlew V.
Management of surgical patients receiving anticoagulation and antiplatelet agents.
Br J Surg 2008 Nov 7; 95(12):1437-1448 [Epub ahead of print]

Alonso-Coello P, Montori VM, Sola I, Schunemann HJ, Devereaux P, Charles C, Roura M, Diaz MG, Souto JC, Alonso R, Oliver S, Ruiz R, Coll-Vinent B, Diez AI, Gich I, Guyatt G.
Values and preferences in oral anticoagulation in patients with atrial fibrilation: physicians' and patients' perspectives. Protocol for a two-phase study.
BMC Health Serv Res. 2008 Oct 27;8(1):221. [Epub ahead of print]

Cohen M, Hoekstra J
The use of adjunctive anticoagulants in patients with acute coronary syndrome transitioning to percutaneous coronary intervention
Am J Emerg Med 2008 Oct;26(8):932-41.

Connolly SJ, Pogue J, Eikelboom J, Flaker G, Commerford P, Franzosi MG, Healey JS, Yusuf S; on behalf of the ACTIVE W Investigators
Benefit of Oral Anticoagulant Over Antiplatelet Therapy in Atrial Fibrillation Depends on the Quality of International Normalized Ratio Control Achieved by Centers and Countries as Measured by Time in Therapeutic Range
Circulation 2008 Oct 27 [Epub ahead of print]

Eischer L, Gartner V, Schulman S, Kyrle PA, Eichinger S; for the AUREC-FVIII investigators (as listed in acknowledgements)
6 versus 30 months anticoagulation for recurrent venous thrombosis in patients with high factor VIII
Ann Hematol 2008 Oct 18. [Epub ahead of print]

Furusho H, Takamura M, Takata S, Sakagami S, Hirazawa M, Kato T, Murai H, Okajima M, Kaneko S
Current Status of Anticoagulation Therapy for Elderly Atrial Fibrillation Patients in Japan
Circ J 2008 Oct 14. [Epub ahead of print]

Janin S, Meneveau N, Mahemuti A, Descotes-Genon V, Dutheil J, Chopard R, Seronde MF, Schiele F, Bernard Y, Bassand JP
Safety and efficacy of fondaparinux as an adjunctive treatment to thrombolysis in patients with high and intermediate risk pulmonary embolism.
J Thromb Thrombolysis 2008 Oct 25 [Epub ahead of print]

Jolobe OM
Intensity of anticoagulation in octogenarians with nonvalvular atrial fibrillation
J Am Geriatr Soc 2008 Oct;56(10):1967-8

Komotar RJ, Starke RM, Connolly ES Jr
Orally administered factor xa inhibitor, rivaroxaban: a novel thromboembolic prophylaxis agent.
Neurosurgery 2008 Oct;63(4):N10-1

Laporte S, Mismetti P, Decousus H; RIETE Investigators
Clinical Predictors for Fatal Pulmonary Embolism in 15,520 Patients with Venous Thromboembolism: Findings from the Registro Informatizado de la Enfermedad Thrombo Embolica Venosa (RIETE) Registry.
J Vasc Surg 2008 Oct;48(4):1063

Limdi NA, Beasley TM, Crowley MR, Goldstein JA, Rieder MJ, Flockhart DA, Arnett DK, Acton RT, Liu N
VKORC1 polymorphisms, haplotypes and haplotype groups on warfarin dose among African-Americans and European-Americans.
Pharmacogenomics 2008 Oct;9(10):1445-58.

Nieuwlaat R, Connolly S
Stroke prevention in atrial fibrillation: better use of anticoagulation and new agents will lead to improved outcomes.
Heart 2008 Oct 24 [Epub ahead of print]

Osborne NH, Wakefield TW, Henke PK
Venous Thromboembolism in Cancer Patients Undergoing Major Surgery.
Ann Surg Oncol 2008 Oct 8 [Epub ahead of print]

Parvizi J, Azzam K, Rothman RH
Deep venous thrombosis prophylaxis for total joint arthroplasty: American Academy of Orthopaedic Surgeons guidelines.
J Arthroplasty 2008 Oct;23(7 Suppl):2-5

Raghavan N, Frost CE, Yu Z, He K, Zhang H, Humphreys WG, Pinto D, Chen S, Bonacorsi S, Wong PC, Zhang D
Apixaban metabolism and pharmacokinetics following oral administration to humans.
Drug Metab Dispos 2008 Oct 2 [Epub ahead of print]

Ramos J, Perrotta C, Badariotti G, Berenstein G
Interventions for preventing venous thromboembolism in adults undergoing knee arthroscopy.
Cochrane Database Syst Rev 2008 Oct 8;(4):CD005259

Rose AJ, Ozonoff A, Henault LE, Hylek EM
Warfarin for atrial fibrillation in community-based practise.
J Thromb Haemost. 2008 Oct; 6(10):1647-54

Sandercock PA, Counsell C, Kamal AK
Anticoagulants for acute ischaemic stroke.
Cochrane Database Syst Rev 2008 Oct 8; (4):CD000024

Testroote M, Stigter W, de Visser DC, Janzing H
Low molecular weight heparin for prevention of venous thromboembolism in patients with lower-leg immobilization.
Cochrane Database Syst Rev 2008 Oct 8;(4):CD006681.

Tick LW, Kramer MH, Rosendaal FR, Faber WR, Doggen CJ.
Risk factors for post-thrombotic syndrome in patients with a first deep venous thrombosis.
J Thromb Haemost 2008 Oct 4 [Epub ahead of print]

Walker AM, Bennett D
Epidemiology and outcomes in patients with atrial fibrillation in the United States.
Heart Rhythm. 2008 Oct; 5(10):1365-72 Epub 2008 Jul 17.

Bauer KA
New anticoagulants
Curr Opin Hematol 2008 Sep;15(5):509-15

Callaghan JJ, Warth LC, Hoballah JJ, Liu SS, Wells CW
Evaluation of deep venous thrombosis prophylaxis in low-risk patients undergoing total knee arthroplasty
J Arthroplasty 2008 Sep;23(6 Suppl 1):20-4

Douketis J, Cook D, Meade M, Guyatt G, Geerts W, Skrobik Y, Albert M, Granton J, Hébert P, Pagliarello G, Marshall J, Fowler R, Freitag A, Rabbat C, Anderson D, Zytaruk N, Heels-Ansdell D, Crowther M; Canadian Critical Care Trials Group
Prophylaxis against deep vein thrombosis in critically ill patients with severe renal insufficiency with the low-molecular-weight heparin dalteparin: an assessment of safety and pharmacodynamics: the DIRECT study
Arch Intern Med 2008 Sep 8;168(16):1805-12

Douketis JD
Prevention of venous thromboembolism in hospitalized medical patients: addressing some practical questions
Curr Opin Pulm Med 2008 Sep;14(5):381-8

Fuji T, Ochi T, Niwa S, Fujita S
Prevention of postoperative venous thromboembolism in Japanese patients undergoing total hip or knee arthroplasty: two randomized, double-blind, placebo-controlled studies with three dosage regimens of enoxaparin
J Orthop Sci 2008 Sep;13(5):442-51. Epub 2008 Oct 9

Hu D, Sun Y
Epidemiology, risk factors for stroke, and management of atrial fibrillation in China.
Am Coll Cardiol 2008 Sep 2;52(10):865-8

Kwong LM, Happe LE, Horblyuk R, Farrelly E
Decreased venous thromboembolism with injectable vs oral anticoagulation after discharge for major orthopedic surgery.
J Arthroplasty 2008 Sep;23(6 Suppl 1):25-30.

Lee A
VTE in Patients with Cancer-Diagnosis, Prevention, and Treatment.
Thromb Res 2008 Sep 26 [Epub ahead of print]

Lopes RD, Piccini JP, Hylek EM, Granger CB, Alexander JH
Antithrombotic therapy in atrial fibrillation: guidelines translated for the clinician.
J Thromb Thrombolysis 2008 Sep 21. [Epub ahead of print]

Mueck W, Borris LC, Dahl OE, Haas S, Huisman MV, Kakkar AK, Kälebo P, Muelhofer E, Misselwitz F, Eriksson BI
Population pharmacokinetics and pharmacodynamics of once- and twice-daily rivaroxaban for the prevention of venous thromboembolism in patients undergoing total hip replacement.
Thromb Haemost 2008 Sep; 100(3):453-61

Righini M, Bounameaux H
Clinical relevance of distal deep vein thrombosis.
Curr Opin Pulm Med 2008 Sep;14(5):408-13

Schelleman H, Limdi NA, Kimmel SE
Ethnic differences in warfarin maintenance dose requirement and its relationship with genetics.
Pharmacogenomics 2008 Sep; 9(9):1331-46

Schellong SM
Venous ultrasonography in symptomatic and asymptomatic patients: an updated review.
Curr Opin Pulm Med 2008 Sep; 14(5):374-80

Seitz CS, Brocker EB, Trautmann A
Management of allergy to heparins in postoperative care: subcutaneous allergy and intravenous tolerance.
Dermatol Online J 2008 Sep 15;14(9):4

Seto AC, Kenyon K, Wittkowsky AK
Discrepancies in identification of major bleeding events in patients taking warfarin.
Pharmacotherapy 2008 Sep; 28(9):1098-103

Shen AY, Chen W, Yao JF, Brar SS, Wang X, Go AS
Effect of race/ethnicity on the efficacy of warfarin : potential implications for prevention of stroke in patients with atrial fibrillation.
CNS Drugs 2008; 22(10):815-25

Stangier J, Stähle H, Rathgen K, Roth W, Shakeri-Nejad K
Pharmacokinetics and Pharmacodynamics of Dabigatran Etexilate, an Oral Direct Thrombin Inhibitor, Are Not Affected by Moderate Hepatic Impairment.
J Clin Pharmacol. 2008 Sep 30 [Epub ahead of print]

Tanne JH
Most patients at risk of stroke fail to get adequate anticoagulation.
BMJ 2008 Sep 4; 337:a1529. doi: 10.1136/bmj.a1529.

Torbicki A, Perrier A, Konstantinides S, Agnelli G, Galiè N, Pruszczyk P, Bengel F, Brady AJ, Ferreira D, Janssens U, Klepetko W, Mayer E, Remy-Jardin M, Bassand JP, Vahanian A, Camm J, De Caterina R, Dean V, Dickstein K, Filippatos G, Funck-Brentano C, Hellemans I, Kristensen SD, McGregor K, Sechtem U, Silber S, Tendera M, Widimsky P, Zamorano JL, Zamorano JL, Andreotti F, Ascherman M, Athanassopoulos G, De Sutter J, Fitzmaurice D, Forster T, Heras M, Jondeau G, Kjeldsen K, Knuuti J, Lang I, Lenzen M, Lopez-Sendon J, Nihoyannopoulos P, Perez Isla L, Schwehr U, Torraca L, Vachiery JL; Task Force for the Diagnosis and Management of Acute Pulmonary Embolism of the European Society of Cardiology
Guidelines on the diagnosis and management of acute pulmonary embolism: the Task Force for the Diagnosis and Management of Acute Pulmonary Embolism of the European Society of Cardiology (ESC).
Eur Heart J 2008 Sep;29(18):2276-315. Epub 2008 Aug 30.

Trujillo-Santos J, Nieto JA, Tiberio G, Piccioli A, Di Micco P, Prandoni P, Monreal M; RIETE Registry
Predicting recurrences or major bleeding in cancer patients with venous thromboembolism. Findings from the RIETE Registry.
Thromb Haemost 2008 Sep;100(3):435-9

Wiedermann CJ, Stockner I
Warfarin-induced bleeding complications - clinical presentation and therapeutic options.
Thromb Res 2008; 122 Suppl 2:S13-8

Zhou Z, Hu D
An Epidemiological Study on the Prevalence of Atrial Fibrillation in the Chinese Population of Mainland China.
J Epidemiol 2008 Sep 8 [Epub ahead of print]

Acosta S, Alhadad A, Svensson P, Ekberg O.
Epidemiology, risk and prognostic factors in mesenteric venous thrombosis.
Br J Surg 2008 Aug 21. [Epub ahead of print]

Ageno W, Dentali F.
Venous thromboembolism and arterial thromboembolism. Many similarities, far beyond thrombosis per se.
Thromb Haemost 2008 Aug;100(2):181-3.

Aissaoui N, Martins E, Mouly S, Weber S, Meune C.
A meta-analysis of bed rest versus early ambulation in the management of pulmonary embolism, deep vein thrombosis, or both.
Int J Cardiol 2008 Aug 6. [Epub ahead of print]

Besser M, Baglin C, Luddington R, van Hylckama Vlieg A, Baglin T
High Rate of Unprovoked Recurrent Venous Thrombosis is Associated with a High Thrombin Generating Potential in a Prospective Cohort Study
J Thromb Haemost 2008 Aug 1. [Epub ahead of print]

Borris LC, Breindahl M, Lassen MR, Pap AF, Misselwitz F
Differences in Urinary Prothrombin Fragment 1+2 Levels After Total Hip Replacement in Relation to Venous Thromboembolism and Bleeding Events
J Thromb Haemost 2008 Aug 1. [Epub ahead of print]

Bungard TJ, Koshman SL, Tsuyuki RT
Patient preferences for ongoing warfarin management after receiving care by an anticoagulation management service
Am J Health Syst Pharm 2008 Aug 15;65(16):1498-500

Clark NP, Witt DM, Delate T, Trapp M, Garcia D, Ageno W, Hylek EM, Crowther MA
Thromboembolic Consequences of Subtherapeutic Anticoagulation in Patients Stabilized on Warfarin Therapy: The Low INR Study
Pharmacotherapy 2008 Aug;28(8):960-7

Gallus A
Which patients with venous thromboembolism are at risk for fatal pulmonary embolism?
Nat Clin Pract Cardiovasc Med 2008 Aug 5. [Epub ahead of print]

Gladstone DJ, Bui E, Fang J, Laupacis A, Lindsay MP, Tu JV, Silver FL, Kapral MK
Potentially Preventable Strokes in High-Risk Patients With Atrial Fibrillation Who Are Not Adequately Anticoagulated.
Stroke 2008 Aug 28 [Epub ahead of print]

Gulseth MP, Michaud J, Nutescu EA
Rivaroxaban: an oral direct inhibitor of factor Xa.
Am J Health Syst Pharm 2008 Aug 15;65(16):1520-9

Ho WK, Hankey GJ, Eikelboom JW
The incidence of venous thromboembolism: a prospective, community-based study in Perth, Western Australia.
Med J Aust 2008 Aug 4;189(3):144-7

Hylek EM, Frison L, Henault LE, Cupples A
Disparate Stroke Rates on Warfarin Among Contemporaneous Cohorts With Atrial Fibrillation. Potential Insights Into Risk From a Comparative Analysis of SPORTIF III Versus SPORTIF V.
Stroke 2008 Aug 14

Levi M
Self-management of anticoagulation
Expert Rev Cardiovasc Ther 2008 Aug; 6(7):979-85

Akl EA, Barba M, Rohilla S, Terrenato I, Sperati F, Muti P, Schunemann HJ.
Low-Molecular-Weight Heparins are superior to Vitamin K Antagonists for the long term treatment of venous thromboembolism in patients with cancer: a Cochrane systematic review.
J Exp Clin Cancer Res 2008 Jul 18;27(1):21. [Epub ahead of print]

Audebert HJ, Schenk B, Tietz V, Schenkel J, Heuschmann PU
Initiation of Oral Anticoagulation after Acute Ischaemic Stroke or Transient Ischaemic Attack: Timing and Complications of Overlapping Heparin or Conventional Treatment
Cerebrovasc Dis 2008 Jul 15;26(2):171-177. [Epub ahead of print]

Barnes GD, Froehlich JB
Anticoagulation: where we are and where we need to go
J Thromb Thrombolysis 2008 Jul 18. [Epub ahead of print]

Beri A, Punnam SR
Anticoagulation in Patients with Acute Ischemic Stroke and Atrial Fibrillation-a Balance of Risks and Benefits
2008 Jul 21. [Epub ahead of print]

Brækkan SK, Mathiesen EB, Njølstad I, Wilsgaard T, Størmer J, Hansen JB
Family history of myocardial infarction is an independent risk factor for venous thromboembolism - the Tromsø study
J Thromb Haemost 2008 Jul 26 [Epub ahead of print]

Buller HR, Lensing AW, Prins MH, Agnelli G, Cohen A, Gallus AS, Misselwitz F, Raskob G, Schellong S, Segers A
A dose-ranging study evaluating once-daily oral administration of the factor Xa inhibitor Rivaroxaban in the treatment of patients with acute symptomatic deep vein thrombosis. The EINSTEIN-DVT Dose-Ranging Study
Blood 2008 Jul 11 [Epub ahead of print]

Camporese G, Bernardi E, Prandoni P, Noventa F, Verlato F, Simioni P, Ntita K, Salmistraro G, Frangos C, Rossi F, Cordova R, Franz F, Zucchetta P, Kontothanassis D, Andreozzi GM; KANT (Knee Arthroscopy Nadroparin Thromboprophylaxis) Study Group
Low-molecular-weight heparin versus compression stockings for thromboprophylaxis after knee arthroscopy: a randomized trial
Ann Intern Med 2008 Jul 15;149(2):73-82

Collen JF, Jackson JL, Shorr AF, Moores LK
Prevention of venous thromboembolism in neurosurgery: a meta-analysis
Chest 2008 Jul 18. [Epub ahead of print]

Douen AG, Sabih M, Pageau N
Thrombus detection by echocardiography in patients with acute ischemic stroke and chronic or new-onset atrial fibrillation
J Stroke Cerebrovasc Dis 2008 Jul-Aug;17(4):208-11

Dunning J, Versteegh M, Fabbri A, Pavie A, Kolh P, Lockowandt U, Nashef SA; on behalf of the EACTS Audit and Guidelines Committee
Guideline on antiplatelet and anticoagulation management in cardiac surgery
Eur J Cardiothorac Surg 2008 Jul;34(1):73-92. Epub 2008 Mar 28.

Fulco PP, Zingone MM, Higginson RT
Possible antiretroviral therapy-warfarin drug interaction
Pharmacotherapy 2008 Jul;28(7):945-9

Hallevi H, Albright KC, Martin-Schild S, Barreto AD, Savitz SI, Escobar MA, Gonzales NR, Noser EA, Illoh K, Grotta JC
Anticoagulation After Cardioembolic Stroke: To Bridge or Not to Bridge?
Arch Neurol 2008 Jul 14. [Epub ahead of print]

Kakkar AK, Brenner B, Dahl OE, et al., for the RECORD2 investigators.
Extended duration rivaroxaban versus short-term enoxaparin for the prevention of venous thromboembolism after total hip arthroplasty: a double-blind, randomised controlled study.
The Lancet 2008; 372:31-39

Khoobiar S, Mejevoi N, Kaid K, Boiangiu C, Setty S, Tanwir A, Khalid K, Cohen M
Primary percutaneous coronary intervention for ST-elevation myocardial infarction using an intravenous and subcutaneous enoxaparin low molecular weight heparin regimen.
J Thromb Thrombolysis 2008 Jul 18 [Epub ahead of print]

Manzano-Fernández S, Pastor FJ, Marín F, Cambronero F, Caro C, Pascual-Figal DA, Garrido IP, Pinar E, Valdés M, Lip GY
Increased major bleeding complications related to triple antithrombotic therapy usage in patients with atrial fibrillation undergoing.
Chest 2008 Jul 18. [Epub ahead of print]

Paauw JD, Borders H, Ingalls N, Boomstra S, Lambke S, Fedeson B, Goldsmith A, Davis AT
The Incidence of PICC Line-Associated Thrombosis With and Without the Use of Prophylactic Anticoagulants.
JPEN J Parenter Enteral Nutr 2008 July-August;32(4):443-447.

Sandercock PA, Counsell C, Tseng MC
Low-molecular-weight heparins or heparinoids versus standard unfractionated heparin for acute ischaemic stroke.
Cochrane Database Syst Rev 2008 Jul 16;(3):CD000119.

Savi P, Herault JP, Duchaussoy P, Millet L, Schaeffer P, Petitou M, Bono F, Herbert JM
Reversible biotinylated oligosaccharides. A new approach for a better management of anticoagulant therapy.
J Thromb Haemost 2008 Jul 19 [Epub ahead of print]

Verheugt FW
Long-term anticoagulation in patients with coronary disease, and future developments.
Curr Opin Cardiol 2008 Jul;23(4):315-9